Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human neurofibromatosis type 1 therapeutic vaccine
- Development stage
- Preclinical
- Lead developer
- Calviri
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Calviri's Human Neurofibromatosis Type 1 (NF-1) Therapeutic Vaccine is an off-the-shelf cancer vaccine based on the Recurrent Expressed Deletion Neoantigen (REDN) platform. It is designed to target specific neoantigens identified through Calviri's proprietary REDN Discovery chips, which detect frameshift mutations and other recurrent neoantigens common in NF-1-associated tumors. The vaccine aims to stimulate a robust anti-tumor immune response in pediatric patients with NF-1-associated brain cancers, specifically pediatric gliomas. The program is currently in IND-enabling development in partnership with Children's National Hospital.
- Other names
- Human NF-1 Therapeutic VaccineNF-1 Therapeutic VaccineNF1 Therapeutic VaccineNF 1 Therapeutic Vaccinehuman neurofibromatosis type 1 therapeutic vaccine
02
Targets
NF1-REDN-HLA (Neurofibromin 1 RNA-error-derived neoantigen-HLA complex)
Beyond the preview
Go deeper on human neurofibromatosis type 1 therapeutic vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human neurofibromatosis type 1 therapeutic vaccine.